Can price controls reduce pharmaceutical expenses? A case study of antibacterial expenditures in 12 Chinese Hospitals from 1996 to 2005

International Journal of Health Services

Volumn 43, Issue 1, 2013, Pages 91-103

  Han, Sheng ^a   Liang, Huigang ^a   Su, Weiping ^a   Xue, Yajiong ^a   Shi, Luwen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

DRUG; EXPENDITURE; HEALTH SERVICES; HOSPITAL SECTOR; PRICE DETERMINATION; PRICING POLICY; PUBLIC SPENDING;

ARTICLE; CHINA; COST CONTROL; DRUG COST; ECONOMICS; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITAL PHARMACY; HUMAN; INAPPROPRIATE PRESCRIBING; LEGAL ASPECT; METHODOLOGY; STANDARD;

ANTI-BACTERIAL AGENTS; CHINA; COST CONTROL; DRUG COSTS; FINANCING, GOVERNMENT; GOVERNMENT REGULATION; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; INAPPROPRIATE PRESCRIBING; PHARMACY SERVICE, HOSPITAL;

BEIJING [CHINA]; CHINA;

EID: 84873584628     PISSN: 00207314     EISSN: 15414469     Source Type: Journal    
DOI: 10.2190/HS.43.1.g     Document Type: Article

References (30)

1. Han, S., and Shi, L. A study of index system method for factor analyzing on drug expense. China J. Pharm. Econ. 6:36-41, 2009.
2. Hay, D. Economic reform and state-owned enterprises in China, 1979-1987. Oxford University Press, Oxford, 2002.
3. Dollar, D. Economic Reform and Allocative Efficiency in China's State-Owned Industry. Econ. Dev. Cult. Change 39(1):89-105, 1990.
4. Chinese Ministry of Health. Several Policy Issues on Health Reform. 1985. http://www.people.com.cn/item/flfgk/gwyfg/1985/112708198501.html.
5. Chinese Ministry of Health. 4-1-1 Total Health Expenditure in Annual Reports of Chinese Health Statistics 2009. Peking Union Medical College, Beijing, 2009. http://www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ ptjnj/year2009/t-4.htm.
6. The World Bank. Fixing the Public Hospital System in China. 2010. http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resources/ 281627-1285186535266/FixingthePublicHospitalSystem.pdf.
7. Ni, Q. Drug price index method discussion. Chin. Pharm. (21):801-804, 2007.
8. Zhang, Z. Z. The Report of Health Cost Accounting in China. People's Medical Press, Beijing, 2009.
9. Tang, S. C., and Zhang, X. P. The re-understanding of drug prices and drug costs. J. Chin. Health Econ. 27(3):53-55, 2008.
10. Liu, G. E., and Tan, Y. Trend analysis of Chinese drug costs. J. Chin. Health Econ. 26(12):5-6, 2007.
11. Wang, L. H. Causes of artificially high drug costs and countermeasures. Heilongjiang Medicine 21(5):80-81, 2008.
12. Liang, H., Ding, J., and Xue, Y. China's drug innovation and policy environment. Drug Discovery Today 16(1-2):1-3, 2011.
13. Guan, X., et al. An analysis of China's national essential medicine policy. J. Public Health Pol. (forthcoming).
14. Chen, W. Methodology discussion of drug price index weave. Chin. Health Econ. 14(8):29-31, 1995.
15. China Medical Economic Information Network. http://www.cmei.org.cn.
16. Liang, H., et al. Electronic data interchange usage in China's healthcare organizations: The case of Beijing's hospitals. Int. J. Inform. Manag. 24(6):507-522, 2004.
17. Addis, A., and Magrini, N. New approaches to analyzing prescription data and to transfer pharmacoepidemiological and evidence-based report to prescribers. Pharmacoepidemiol. Drug Saf. 11(8):721-726, 2002.
18. Martini, N. The Use of Medicines in Italy. Tipolitografia Quattroventi, Rome, 2005.
19. Morgan, S., Bassett, K., and Mintzes, B. Outcomes-based drug coverage in British Columbia. Health Aff. 23:269-276, 2004.
20. Morgan, S. Drug spending in Canada. Med. Care 42(7):635-641, 2004.
21. Gerdtham, U.-G., et al. Price indices of drugs and the switching to new drugs. Phar-macoeconomics 13(1 Pt 1):71-80, 1997.
22. Patricia, M., Danzon, J., and Kim, D. International price comparisons for pharmaceuticals. Pharmacoeconomics 14(Suppl. 1):115-128, 1998.
23. World Health Organization Collaborating Center for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment, Ed. 7. Norwegian Institute of Public Health, Oslo, 2004.
24. Lichtenberg, F. R. The impact of new drug launches on longevity: Evidence from longitudinal, disease-level data from 52 countries, 1982-2001. Int. J. Health Care Finance Econ, 5:47-73, 2005.
25. Abelson, P. The value of life and health for public policy. Econ. Rec. 79(Suppl.): S2-S13, 2003.
26. Pauly, M. V. Measures of costs and benefits for drugs in cost effectiveness analysis. In Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, eds. F. A. Sloan and C. R. Hsieh. Cambridge University Press, New York, 2007.
27. Murphy, K., and Topel, R. H. The economic value of medical research. In Measuring the Gains from Medical Research: An Economic Approach, eds. K. M. Murphy and R. H. Topel. University of Chicago Press, Chicago, 2003.
28. Vernon, J. A. Drug Research and Price Control, Health & Medicine, 2002-2003. PhRMA-Department of Commerce, Foreign Government Pharmaceutical Price and Access Controls, July 1, 2004.
29. Rovira, J., et al. The Role of Prices in Drug Expenditure Analysis. HEPAC 2:142-149, 2001.
30. Griliches, Z., and Cockburn, I. Generic and new goods in pharmaceutical price indexes. Am. Econ. Rev. 5:1213-1232, 1994.